{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:12:02Z","timestamp":1748333522170,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Psoriatic arthritis (PsA) presents a unique clinical challenge. Affecting joints, skin, nails, and other organs, it is associated with various comorbidities and has a significant impact on quality of life, social participation and working life. While biologic and other targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) have revolutionised therapy, questions remain about the long-term safety of these agents, and their effectiveness and cost-effectiveness in the real-world clinical setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>The British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA) is a prospective registry of patients with PsA, recruited from across Great Britain, who are (a) commencing a bDMARD\/tsDMARD; or (b) na\u00efve to all bDMARDs\/tsDMARDs. Ethical approval was given by the NHS West of Scotland Research Ethics Committee 3 (reference: 18\/WS\/0126). Clinical data are extracted from participants\u2019 medical records, including symptom onset and diagnosis, joint, skin and nail symptoms, dactylitis and enthesitis. Physical measurements (height, weight and 66\/68 joint counts) and a detailed drug history are taken. Participants are also asked to complete questionnaires comprising instruments relating to general health and quality of life, axial disease, sleep and fatigue, impact of disease, functional status, mental health, other symptoms, and occupational status. The study duration is 5 years in the first instance, and all participants are followed up annually until the end of the study. Participants commencing a bDMARD\/tsDMARD are also followed up three and six months after the start of therapy. Disease activity, including C-reactive protein, is assessed at each visit; and participants from some centres are invited to donate blood and urine samples for the creation of a biobank.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Complementing data from randomised trials, results from this study will contribute to the evidence base underpinning the clinical management of psoriatic arthritis. Various analyses will determine the effectiveness and safety of bDMARDs\/tsDMARDs in the real-world, will examine the clinical and biological predictors of treatment response, and will provide real-world data on the cost-effectiveness of these therapies, as well as providing informative data important to patients such as quality of life and occupational outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The full study protocol is registered on the Open Science Framework (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/osf.io\/jzs8n\">https:\/\/osf.io\/jzs8n<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41927-021-00189-0","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T23:03:15Z","timestamp":1621206195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-7591","authenticated-orcid":false,"given":"Gareth T.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Macfarlane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Forrest Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"McNamee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen R.","family":"Neilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. David","family":"Burden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"189_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499\u2013510.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"189_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/acr.23789","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res. 2019;71(1):229.","journal-title":"Arthritis Care Res"},{"key":"189_CR3","unstructured":"National Institute for Health and Care Excellence. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199). Published: 25-Aug-2010. Available from: www.nice.org.uk\/guidance\/ta199."},{"key":"189_CR4","unstructured":"National Institute for Health and Care Excellence. Golimumab for the treatment of psoriatic arthritis (TA220). Published: 27-Apr-2011. Available from: www.nice.org.uk\/guidance\/ta220."},{"key":"189_CR5","unstructured":"National Institute for Health and Care Excellence. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. Published: 24-May-2017. Available from: www.nice.org.uk\/guidance\/ta445."},{"key":"189_CR6","doi-asserted-by":"crossref","unstructured":"Jones GT, Dean LE, Pathan E, Hollick RJ, Macfarlane GJ. Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials? Ann Rheum Dis. 2020;79(7):914\u20139.","DOI":"10.1136\/annrheumdis-2019-216841"},{"issue":"8","key":"189_CR7","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"189_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686\u201391. https:\/\/doi.org\/10.1002\/art.23568.","journal-title":"Arthritis Rheum"},{"key":"189_CR9","doi-asserted-by":"crossref","unstructured":"Ader DN. Developing the Patient-Reported Outcomes Measurement Information System (PROMIS). Medical Care 2007;45(5):S1-S2.","DOI":"10.1097\/01.mlr.0000260537.45076.74"},{"issue":"5","key":"189_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3899\/jrheum.100857","volume":"38","author":"A Cauli","year":"2011","unstructured":"Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38(5):898\u2013903. https:\/\/doi.org\/10.3899\/jrheum.100857.","journal-title":"J Rheumatol"},{"issue":"12","key":"189_CR11","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing spondylitis disease activity index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"4","key":"189_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0895-4356(88)90138-2","volume":"41","author":"CD Jenkins","year":"1988","unstructured":"Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol. 1988;41(4):313\u201321. https:\/\/doi.org\/10.1016\/0895-4356(88)90138-2.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"189_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3899\/jrheum.100594","volume":"38","author":"F Wolfe","year":"2011","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, H\u00e4user W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38(6):1113\u201322. https:\/\/doi.org\/10.3899\/jrheum.100594.","journal-title":"J Rheumatol"},{"issue":"1","key":"189_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7\u201322. https:\/\/doi.org\/10.1002\/hec.3564.","journal-title":"Health Econ"},{"issue":"2","key":"189_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/ard.2003.006296","volume":"63","author":"SP McKenna","year":"2004","unstructured":"McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale D. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004;63(2):162\u20139. https:\/\/doi.org\/10.1136\/ard.2003.006296.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"189_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI) \u2013 a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"189_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205207.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"189_CR18","first-page":"439","volume":"13","author":"JA Husted","year":"1995","unstructured":"Husted JA, Gladman DD, Long JA, Farewell VT. A modified version of the health assessment questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol. 1995;13(4):439\u201343.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"189_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x.","journal-title":"J Gen Intern Med"},{"issue":"5","key":"189_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"key":"189_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","volume":"117","author":"HA Sampson","year":"2006","unstructured":"Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report \u2013 second National Institute of allergy and infectious disease\/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"189_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O FitzGerald","year":"2015","unstructured":"FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17(1):115\u201325. https:\/\/doi.org\/10.1186\/s13075-015-0640-3.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"189_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15suppl1-01","volume":"15","author":"M Rodgers","year":"2011","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15(10):1\u2013329.","journal-title":"Health Technol Assess"},{"issue":"1","key":"189_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353. https:\/\/doi.org\/10.1136\/ard.2008.102053.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"189_CR25","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/rheumatology\/kew053","volume":"55","author":"EM Dennison","year":"2016","unstructured":"Dennison EM, Packham J, Hyrich K. The BSRBR-RA at 15 years. Rheumatology. 2016;55(12):2093\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kew053.","journal-title":"Rheumatology"},{"issue":"3","key":"189_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","volume":"166","author":"AD Burden","year":"2012","unstructured":"Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, et al. The British Association of Dermatologists' biologic interventions register (BADBIR): design, methodology and objectives. Br J Dermatol. 2012;166(3):545\u201354. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10835.x.","journal-title":"Br J Dermatol"},{"issue":"56","key":"189_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21560","volume":"21","author":"M Corbett","year":"2017","unstructured":"Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, et al. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017;21(56):1\u2013326. https:\/\/doi.org\/10.3310\/hta21560.","journal-title":"Health Technol Assess"},{"issue":"10","key":"189_CR28","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1002\/art.34627","volume":"64","author":"G Schett","year":"2012","unstructured":"Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64(10):3156\u201367. https:\/\/doi.org\/10.1002\/art.34627.","journal-title":"Arthritis Rheum"},{"issue":"38","key":"189_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta9380","volume":"9","author":"C Bartlett","year":"2005","unstructured":"Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess. 2005;9(38):1\u2013152.","journal-title":"Health Technol Assess"},{"issue":"7","key":"189_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.18553\/jmcp.2018.24.7.623","volume":"24","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database. J Manag Care Spec Pharm. 2018;24(7):623\u201331. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.623.","journal-title":"J Manag Care Spec Pharm"},{"key":"189_CR31","volume-title":"Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation","author":"M Corbett","year":"2016","unstructured":"Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, et al. Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Southampton: NIHR Journals Library; 2016. (Health Technology Assessment, No. 20.9.). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK343703"},{"issue":"suppl 3","key":"189_CR32","first-page":"iii118","volume":"57","author":"GT Jones","year":"2018","unstructured":"Jones GT, Macfarlane GJ, Pathan E, McNamee P, Neilson AR. Quality of life estimation in economic evaluations and healthcare decision-making: different approaches, different results. Results from the British Society for Rheumatology biologics register in Ankylosing spondylitis (BSRBR-AS). Rheumatology. 2018;57(suppl 3):iii118.","journal-title":"Rheumatology"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-021-00189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-021-00189-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-021-00189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T23:04:09Z","timestamp":1621206249000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-021-00189-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["189"],"URL":"https:\/\/doi.org\/10.1186\/s41927-021-00189-0","relation":{},"ISSN":["2520-1026"],"issn-type":[{"type":"electronic","value":"2520-1026"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the NHS West of Scotland Research Ethics Committee 3 (reference: 18\/WS\/0126). All participants provide written informed consent prior to participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript contains no personal or clinical details of study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GTJ Has received research grant income from AbbVie, Amgen (previously Celgene), Pfizer, UCB and GSK. GJM Has received research grant income from AbbVie, Amgen (previously Celgene), Pfizer, UCB and GSK. KFK Nil. PM Nil. ARN Nil. SS Has received research grants or honoraria from AbbVie, Amgen (previously Celgene), BMS, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer and UCB. ADB Has received research grants or honoraria from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Leo, Lilly, Novartis and UCB LK Nil. PSH Has received research grant income from AbbVie, Janssen and Novartis; has received honoraria or consultation fees from Celgene and Galapagos; and has received honoraria or consultation fees paid to charity from AbbVie, Amgen, Pfizer and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}